Summary of the Invention: The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. The vaccine composition of the present invention has as active principle a chemical conjugated between the human recombinant Epidermal Growth Factor (hrEGF) and the P64K recombinant protein. In another embodiment, the present invention relates to the conjugation procedure to obtain, a chemical conjugated under controlled and reproducible parameters. In a preferred embodiment, the present invention relates to the procedure for purifying the chemical conjugated with a higher purity of the therapeutical vaccine composition, and a surprisingly increased immunogenic activity, inducing a significant increase of the anti-EGF antibody titers in humans. Additionally the present invention provides the methodology to obtain a vaccine composition in several dose presentations (total milligrams of conjugated EGF-P64K/vial). The versatility of the dose presentation allows increasing the immunization dose per patient, without increasing the frequency of injections and / or immunization sites. Besides, the present invention relates to a sanitary procedure for obtaining a vaccine composition for parenteral route in the cancer therap.Kompozicija za vakcinu koja sadrži aktivni element konjugovanog proteina hrEGF-rP64K, pri čemu je svaki P64K molekul proteina vezan za dva hrEGF molekula i pri čemu kompozicija za vakcinu sadrži bar 90% aktivnog elementa.Prijava sadrži još 15 patentnih zahteva.
